Unique ID issued by UMIN | UMIN000002477 |
---|---|
Receipt number | R000003036 |
Scientific Title | Drug-drug interaction study to explore importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatin |
Date of disclosure of the study information | 2009/09/10 |
Last modified on | 2012/07/13 14:16:55 |
Drug-drug interaction study to explore
importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatin
Drug-drug interaction study on atorvastatin
Drug-drug interaction study to explore
importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatin
Drug-drug interaction study on atorvastatin
Japan |
healthy male subjects
Not applicable |
Others
YES
To examine the effects of functional variation of OATP1B1and CYP3A4 on pharmacokinetics of atorvastatin in japanese healthy subjects by using microdose.
Others
gene analysis
pharmacokinetic of atorvastatin
pharmacokinetics of midazolam, pravastatin, itraconazole and rifampicin
gene analysis
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Drug administration(microdose of atorvastatin,midazolam,pravastatin)->(over 1week for washout)->Drug administration(clinical dose of rifampicin,microdose of atorvastatin, midazolam,pravastatin)->(over 1week for washout)->Drug administration(clinical dose of itraconazole,microdose of atorvasutatin, midazolam, pravastatin)
20 | years-old | <= |
40 | years-old | > |
Male
1)Ability to understand and willing to sign the informed consent.
2)Japanese healthy male subjects age 20 to 40 years of age
3)Weight between 50-100kg.
4)Healthy subject as determined by medical history, physical examination, ECGs, and clinical laboratory tests.
1)Any hypersensitivities to atorvastatin,midazolam,pravastatin, straconazole or rifampicin.
2)hepatic disease requiring treatment.
3)acute narrow-angle glaucoma
4)QT prolongation over 460ms.
5)Use of medicine or health product including Saint John's wort 2 weeks before pre-dose.
6)Intake of fruit food and drink including grapefruit juice, orange juice or apple juice from 7 days before pre-dose.
7)Participation to any other clinical reseach in the past 3 months.
8)Donating over 200 ml of blood in the past 1 month or over 400ml of blood in the past 3 months.
9)Positive tests of serological reaction for syphilis, HIV antigen and antibody, HBs antigen or HCV antibody.
10)Any allergy to drug and food
11)Drug abuse or positive drug screening
12)Any condition that, in the opinion of the investigator, would make the patient unsuitable for the study.
8
1st name | |
Middle name | |
Last name | Yuji Kumagai |
Kitsato University East Hospital
Clinical trial Center
2-1-1, Asamizodai, Sagamihara, Kanagawa, 228-8520
1st name | |
Middle name | |
Last name |
Kitsato University East Hospital
Clinical trial Center
2-1-1, Asamizodai, Sagamihara, Kanagawa, 228-8520
Clinical trial Center,Kitsato University East Hospital
APDD, Association for Promoting Drug Development
Other
NO
2009 | Year | 09 | Month | 10 | Day |
Partially published
Completed
2009 | Year | 08 | Month | 30 | Day |
2009 | Year | 09 | Month | 01 | Day |
2009 | Year | 11 | Month | 01 | Day |
2009 | Year | 09 | Month | 10 | Day |
2012 | Year | 07 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003036